The Hexal Exit Playbook: What Selling to Novartis for $7.5 Billion Taught the Strüngmanns About Patient Capital
- Jörn Menninger
- 4 days ago
- 6 min read
Updated: 2 days ago
On February 21, 2005, Andreas and Thomas Strüngmann sold Hexal AG and their 67.7% controlling stake in Eon Labs to Novartis for €5.65 billion cash (~$7.5B at the time) — the largest private-company sale in German history at the time. Novartis folded the businesses into Sandoz, creating the world's largest generic-drug company. The brothers' real win was what came next.
Most exit stories end at the press release. The Hexal-Novartis deal is interesting because of what happened after.
In February 2005, Andreas and Thomas Strüngmann walked away from a 19-year build with $7.5 billion in cash. They were 55. They had a generics business that had grown from a single Bavarian factory to one of Europe's largest drug producers. They had a US foothold (Eon Labs). They had a buyer (Novartis) willing to pay top of the cycle to consolidate global generics. The deal was clean: cash, not stock, no earn-outs, no consulting agreements. The brothers cashed out and went home.
What they did with the cash is the actual lesson — and it's the part most exit narratives skip. This piece walks through the 2005 deal structure, the strategic reasoning on both sides, and the playbook the brothers extracted from the experience that they're still running 21 years later.
This is part 2 of the Strüngmann Cluster on Startuprad.io. Sits inside Capital Strategies: How DACH Money Moves.
Executive Summary
The 2005 Hexal sale wasn't just an exit — it was a capital-cycle reset. The brothers extracted three lessons that became the operating principles of Athos Service: (1) sell at the top of the consolidation cycle, not the top of the company; (2) take cash, not stock — optionality over upside; (3) reinvest into adjacent science where you have domain expertise, not into anything you can't evaluate yourself. Those three principles funded BioNTech.
Key Takeaways
Deal structure: €5.65B (~$7.5B at the time) total cash to the brothers for Hexal and their 67.7% Eon Labs stake. Largest private-company sale in German history at the time. Novartis funded primarily through cash and short-term debt.
Strategic logic for Novartis: Sandoz had been a respectable but mid-tier generics player. The combined Hexal + Eon Labs deal made Sandoz the world's #1 generics company overnight, with $200M annual cost synergies projected within three years.
Strategic logic for the Strüngmanns: Generics consolidation was peaking in 2005. Pricing pressure was about to compress margins. Cashing out at the cycle peak was the right call, not the easy one.
The cash-vs-stock decision: Taking cash (not Novartis shares) gave the brothers full optionality to redeploy into early-stage biotech — which they did three years later with BioNTech.
Reinvestment discipline: The brothers didn't diversify into hedge funds, real estate alone, or speculative tech. They went back into life sciences where they could read a science deck.
What Novartis was buying — and what they paid for it
By 2005, Hexal had grown from a 22-employee startup in Holzkirchen, Bavaria (1986) into Germany's second-largest generics company: ~7,000 employees worldwide, €1.11B revenue in 2003, $1.65B in 2004, with the Salutas manufacturing plant in Barleben as one of Europe's most modern automated pharmaceutical factories. The US presence came through the 67.7% controlling stake in Eon Labs, acquired in 1995 and operationally rebuilt by the brothers between 1995-2000.
On February 21, 2005, Novartis announced it would acquire Hexal AG and the Strüngmanns' Eon Labs stake for €5.65 billion in cash (~$7.5B at the time). A subsequent tender offer mopped up the remaining Eon Labs public float.
Novartis already owned Sandoz, its generics division. Pre-deal, Sandoz was a respectable but second-tier player. Adding Hexal's German leadership and Eon Labs' US presence — plus the deep generics-development capability the Strüngmanns had built — created the world's largest generic-drug company in a single move. Novartis projected $200 million in annual cost synergies within three years, primarily from consolidating manufacturing, regulatory, and commercial overhead.
The market read it as a strategic win for Novartis (which had been ceding ground to Teva and Mylan). For the Strüngmanns, it was a disciplined exit at the right moment in the consolidation cycle.
Why 2005 was the right year to sell
Generics is a cyclical business. The economics work when patent expirations create temporary windows of high-margin commercialisation, and they compress when those windows close and price competition takes over. Between 2000 and 2005, the global generics industry was in a consolidation wave: Teva-Sicor (2003), Sandoz-Lek (2002), Watson-Andrx, Mylan-Matrix. Buyers were paying premium multiples to lock in scale. By 2007-2008, the multiples had compressed.
The Strüngmanns sold at top of cycle. They didn't sell because they had to — Hexal was profitable, growing, and well-positioned. They sold because the consolidation premium would not be available indefinitely. That timing discipline became one of the operating principles of Athos.
Why cash, not stock
Novartis offered cash. The brothers took cash. There's a school of thought in M&A that taking acquirer stock signals confidence in the strategic combination — and on the right deal, can deliver enormous upside (Disney-Pixar, Facebook-WhatsApp). The Strüngmanns weren't optimising for upside; they were optimising for optionality.
If they had taken Novartis stock, they'd have been long Novartis (a large-cap pharma stock with predictable returns) for the next decade. They wanted to be free to redeploy. That decision turned out to fund BioNTech. €136.5M of the Hexal proceeds became the BioNTech anchor in 2008, which became a $14B position in 2023. None of that is possible if the brothers are sitting on Novartis shares with restricted-stock vesting schedules and tax friction on rotation.
What they reinvested in (and what they didn't)
The brothers did not diversify into asset classes they couldn't evaluate. They didn't start hedge funds. They didn't buy private equity stakes in retail or industrials. They went back into life sciences — first through smaller biotech bets (Ganymed Pharmaceuticals, where they invested €150M in 2007 and exited via Astellas Pharma in 2016 for up to €1.28B), then through the BioNTech anchor in 2008.
The pattern: every dollar reinvested went into a category the brothers had spent 25 years learning. That's not financial diversification — it's domain compounding. Athos Service today still operates this way: it adds adjacencies (digital health via Doctolib, gene therapy via AAVantgarde) but stays within the life-sciences perimeter where the brothers' judgment is calibrated.
The discipline most family offices miss
There are a lot of European family offices sitting on exit proceeds. Most of them do one of two things: hand the money to private banks (who diversify it across asset classes the family doesn't understand) or chase momentum into whatever sector is hot (in 2021 it was crypto and SPACs; in 2024 it was AI). Both approaches dilute the source of the original wealth: the family's actual operational expertise.
The Strüngmann discipline — sell at the cycle peak, take cash for optionality, reinvest into the science you understand — is the part of the playbook that's hardest to replicate. The exit can be copied. The discipline can't.
Tomorrow we go deeper on the Athos Service model itself — and on how the Strüngmanns and Susanne Klatten have converged on the same Munich ecosystem player. Sunday: Athos vs venture capital.
FAQ
How much did the Strüngmanns get for Hexal? The brothers received approximately $7.5 billion in cash for Hexal AG and their 67.7% controlling stake in Eon Labs. The total deal value to Novartis was approximately $8.3 billion, including the subsequent tender offer for the remaining Eon Labs public float.
Why did Novartis buy Hexal? To create the world's largest generic-drug company in a single move. Novartis already owned Sandoz, but Sandoz was a mid-tier player. The combined Hexal + Eon Labs deal added German market leadership, US presence, and substantial development capability — plus a forecast $200M annual cost synergy within three years.
Why did the Strüngmanns sell? Discipline. Generics consolidation was peaking in 2005, premium multiples were available, and the brothers correctly anticipated that the consolidation premium would compress within a few years. They sold at the top of the cycle, not the top of the company.
Why take cash rather than Novartis stock? For optionality. Cash gave the brothers freedom to redeploy into early-stage biotech (which they did three years later with BioNTech). Novartis stock would have locked them into a large-cap pharma position for years.
What did they do with the proceeds? Founded Athos Service (Munich family office), made smaller life-sciences bets (notably Ganymed in 2007), and anchored BioNTech in 2008 with €136.5M. The €136.5M turned into a ~$14B position by 2023.
More on Startuprad.io
Read more in the Strüngmann Cluster: how the brothers built Germany’s most important biotech family office, Athos Service vs venture capital, and what Athos is funding now in 2026. See also our Twin Billionaires hub and the Capital Strategies: How DACH Money Moves pillar.
About the Author
Joern "Joe" Menninger is the founder of Startuprad.io, Europe's leading English-language startup media platform covering the DACH region. With 740+ podcast episodes and over 1 million annual streams. Connect on LinkedIn
Comments